Pharma channel feed

Up­dat­ed: Drug­mak­ers ben­e­fit 'sub­stan­tial­ly' from sec­ondary patents on in­halers — study

3 years ago
FDA+

Am­gen files brief to Supreme Court ahead of oral ar­gu­ments — with in­dus­try am­i­cus sup­port

3 years ago
Law

Pas­sage of FDA Mod­ern­iza­tion Act 2.0 clears the way to re­duce an­i­mal test­ing

3 years ago
R&D

Sen­ate Fi­nance Chair Wyden con­tin­ues fight over low phar­ma tax rates, this time with BMS

3 years ago

Ab­b­Vie 'Dis­cov­ery Files' do­cuseries de­tails the ori­gin sto­ries of med­i­cines

3 years ago
Marketing

IRA's in­fla­tion-linked re­bates would've saved gov­ern­ment $3.7B from 2018 to 2020 — JA­MA re­search

3 years ago

Can­cer care brand­ing: Will City of Hope and Can­cer Treat­ment Cen­ters of Amer­i­ca brands work ‘bet­ter to­geth­er’?

3 years ago
Marketing

Con­gres­sion­al in­quiry in­to 'high­ly atyp­i­cal' FDA-Bio­gen ties ends with damn­ing re­port, no reper­cus­sions

3 years ago
FDA+

Ac­er, Re­lief win FDA ap­proval for rare meta­bol­ic dis­ease af­ter clear­ing in­spec­tion hur­dles

3 years ago
FDA+

Up­dat­ed: FDA clears first CD20xCD3 bis­pe­cif­ic, giv­ing Genen­tech leg up in a crowd­ed lym­phoma R&D field

3 years ago
R&D
FDA+

FDA qui­et­ly turns Keytru­da ac­cel­er­at­ed ap­proval for less-fre­quent dos­ing in­to full ap­proval

3 years ago
FDA+

Decades of di­ver­si­ty ini­tia­tives lat­er, cer­tain groups re­main 'con­sis­tent­ly un­der­rep­re­sent­ed' in can­cer tri­als, GAO says

3 years ago

Roche's Actem­ra wins ap­proval for hos­pi­tal­ized Covid pa­tients

3 years ago
FDA+
Coronavirus

Up­dat­ed: ICER on Alzheimer's: lecanemab should be priced low­er than Aduhelm

3 years ago

BioSpring in­vests €100M+ in­to new oligonu­cleotide API fa­cil­i­ties in Ger­many

3 years ago
Manufacturing

Vir­ginia Rep. Span­berg­er asks FDA, DEA chiefs to re­spond to Adder­all short­ages

3 years ago
FDA+
Manufacturing

New year, new hire: Mod­er­na taps Mer­ck vet­er­an as lat­est com­mer­cial ex­ec

3 years ago
Marketing

TG's MS hope­ful ubli­tux­imab not cost-ef­fec­tive at Ocre­vus' price, ICER says in ev­i­dence re­port

3 years ago

Cor­rect­ed: Fac­ing decades in prison, two biotech lead­ers charged with wire and se­cu­ri­ties fraud, ly­ing to in­ves­ti­ga­tors

3 years ago
FDA+
Law

Up­dat­ed: Sev­er­al man­u­fac­tur­ers re­port Tam­i­flu short­age as flu sea­son reach­es high point

3 years ago
Manufacturing

Ahead of lecanemab de­ci­sion, Alzheimer's groups pe­ti­tion CMS to re­verse cov­er­age pol­i­cy

3 years ago

Re­al Chem­istry's hol­i­day gift to clients: fight­ing hate speech

3 years ago
Marketing

Om­nibus spend­ing bill fea­tures fund­ing to bol­ster the sup­ply chain and site in­spec­tions

3 years ago
FDA+
Manufacturing

Trends for 2023: What's com­ing next in phar­ma mar­ket­ing and drug com­mer­cial­iza­tion?

3 years ago
Marketing
First page Previous page 154155156157158159160 Next page Last page
A service from the Financial Times